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Edited by Varda RotterAbstract Gossypol is a polyphenolic compound originally iso-
lated from cottonseed that has long been used successfully as a
contraceptive drug for males. However, the molecular mecha-
nism of anti-telomerase eﬀects of gossypol is not entirely under-
stood. In this study, we observed direct cytotoxicity and
inhibition of telomerase activity with downregulation of telome-
rase reverse transcriptase (hTERT) expression. Gossypol treat-
ment resulted in a decrease of c-Myc expression and binding
activity. Gossypol treatment also suppressed the activation of
Akt, thereby inhibiting hTERT phosphorylation and transloca-
tion into the nucleus. We conclude that gossypol regulates the
loss of telomerase activity through transcriptional and posttrans-
lational modiﬁcations of hTERT.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Telomerase is a ribonucleoprotein complex with specialized
reverse transcriptase activity that plays an important role in
maintaining telomere length [1]. The enzyme complex is com-
posed of a catalytic subunit, telomerase reverse transcriptase
(hTERT) [2–4], telomerase RNA (TR) which acts as a tem-
plate [5], telomerase-associated proteins such as TEP1 [6],
and chaperone proteins (p23 and Hsp90) [7]. TR, TEP1, p23,
and Hsp90 are ubiquitously expressed in a wide variety of cells,
irrespective of telomerase activity, however, expression of
hTERT is closely associated with elevated telomerase activity
in a variety of cancer cells [6,7]. Zhang et al. recently demon-
strated that targeting hTERT with RNA interference could
signiﬁcantly suppress telomerase activity and proliferation in
hepatocarcinoma [8]. Previous studies have also demonstrated
that many anti-cancer agents induce apoptosis through tran-Abbreviations: hTERT, telomerase reverse transcriptase; TR, telome-
rase RNA; TRAP, telomeric repeat ampliﬁcation protocol; EMSA,
electrophoretic mobility shift assays; ChIP, chromatin immunoprecip-
itation
*Corresponding author. Fax: +82 64 756 3493.
E-mail address: immunkim@cheju.ac.kr (G.-Y. Kim).
0014-5793/$34.00  2008 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2008.08.029scriptional repression and posttranslational modiﬁcation of
hTERT [9,10]. These studies clearly indicate that basal telome-
rase activity is highly dependent on the expression of the
hTERT.
Expression of hTERT is tightly regulated at the transcrip-
tional level and the proximal 180 bp of the hTERT promoter
is particularly important for maintaining basal transcriptional
activity. Recent studies reported that hTERT is directly con-
trolled by c-Myc activity and also identiﬁed a feasible mecha-
nism of potent anti-cancer activity in gastric carcinoma cells
[11,12]. In addition to transcriptional regulation, hTERT can
also be regulated by posttranslational modiﬁcations. Akt ki-
nase was reported to enhance telomerase activity through
phosphorylation of the hTERT around Ser824 [13].
Gossypol is a polyphenolic compound originally isolated
from cottonseed that has been successfully used as male con-
traceptive drug for a long time [14]. Recently, gossypol was re-
ported to have potent anti-cancer activities in many types of
cancer [15–17]. Gossypol was shown to be a potent Bcl-2/
Bcl-XL small molecule inhibitor [18,19], however, the mecha-
nisms responsible for inhibition of cell growth and stimulation
of apoptosis are completely unknown.
In the present study, we report for the ﬁrst time that gossypol
strongly induces apoptosis and represses telomerase activity via
both transcriptional downregulation and posttranslational
modiﬁcation of hTERT. Transcriptional downregulation in-
volved inactivation of c-Myc, while the posttranslational mod-
iﬁcation involved the inactivation of Akt.2. Materials and methods
2.1. Reagents
Gossypol (98% purity) was purchased from Sigma (St. Louis, MO)
and dissolved in DMSO (vehicle). Antibodies against PARP, hTERT,
c-Myc, and Akt substrate antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Antibodies against p-Akt and anti-
Akt were purchased from Cell Signal (Beverly, MA) and antibody
against b-actin was obtained from Sigma.
2.2. Cell line and culture
Human leukemia U937, HL60, THP-1, and K562 cells were ob-
tained from the American Type Culture Collection (Manassas, VA).
Cells were maintained in RPMI-1640 medium supplemented with
10% heat-inactivated FBS and 1% penicillin–streptomycin (Sigma) in
5% CO2 at 37 C.ation of European Biochemical Societies.
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Cells were seeded at 1 · 105 cells/ml and then treated with the indi-
cated concentrations of gossypol. After 24 h incubation, the cell num-
ber and viability were determined by trypan blue exclusion assay and
MTT assay, respectively. In a parallel experiment, splenocytes were
isolated from ICR and depleted of red cells with ammonium chloride.
Cells were cultured at 37 C in a 5% CO2 humidiﬁed incubator, and
maintained in RPMI 1640 culture medium containing 10% heat-inac-
tivated FBS.2.4. Flow cytometric analysis
Cell cycle and apoptotic death were analyzed by using ﬂow cytome-
try of propidium iodide- and annexin V-stained cells, respectively.
Cells were analyzed by using a FACSCalibur ﬂow cytometer (Becton
Dickenson, San Jose, CA), after staining.
2.5. RNA extraction and RT-PCR
Total RNA was isolated using the Trizol reagent (GIBCO-BRL,
Gaithersburg, MD) according to the manufacturers recommenda-
tions. Genes of interest were ampliﬁed from cDNA which was reverse
transcribed from 1 lg of total RNA using the One-Step RT-PCR Pre-
mix (iNtRON Biotechnology, Sungnam, South Korea). Primers and
conditions for the ampliﬁcation of hTERT and GAPDH have been de-
scribed previously [6].2.6. Western blot analysis
Total cell extracts were prepared using PRO-PREP protein extrac-
tion solution (iNtRON Biotechnology, Sungnam, Republic of Korea).
The preparation of cytoplasmic and nuclear extracts was conducted
using the NE-PER nuclear and cytoplasmic extraction reagents
(Pierce, Rockford, IL). Total cell extracts were separated on 10% poly-
acrylamide gels, and then transferred to nitrocellulose membranes
using standard procedures. The membranes were developed using an
ECL reagent (Amersham, Arlington Heights, IL).
2.7. Telomerase activity assay
Telomerase activity was measured using a PCR-based telomeric re-
peat ampliﬁcation protocol (TRAP) enzyme-linked immunosorbent
assay (ELISA) kit (Boehringer Mannheim, Mannheim, Germany)
according to the manufacturers instructions.2.8. Electrophoretic mobility shift assays (EMSAs)
DNA-protein binding assays were carried out with nuclear extract.
Synthetic complementary c-Myc (5 0-GGA AGC AGA CCA CGT
GGT CTG CTT CC-3) and Sp1 (5 0-ATT CGA TCG GGG CGG
GGCGAG C-3 0) binding oligonucleotides (Santa Cruz Biotechnology)
were 3 0-biotinylated using the biotin 3 0-end DNA labeling kit (Pierce).
2.9. Immunoprecipitation
Total cell extracts were immunoprecipitated with anti-hTERT over-
night at 4 C. Immune complexes were collected using protein A/G-Se-
pharose beads (Santa Cruz Biotechnology), washed, and eluted in
sample buﬀer. Samples were run on 8% SDS–PAGE gels, transferred
to nitrocellulose membranes, and probed with the Akt-substrate anti-
body or hTERT antibody. Blots were developed using the ECL re-
agent.
2.10. Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed using the EZ-Chip assay kit
according to the manufacturers protocol (Upstate Biotechnology,
Lake Placid, NY). The primers used for the ampliﬁcation of hTERT
promoter region were c-Myc (forward): 5 0-AGT GGA TTC GCG
GGC ACA GA-3 0 and c-Myc (forward): 5 0-TTC CCA CGT GCG
CAG CAG GA-3 0 (reverse) (257 bp DNA product) [20].
2.11. Immunoﬂuorescence and nuclear staining
After treatment with gossypol for 24 h, cells were harvested, washed
in ice-cold PBS, ﬁxed with 3.7% paraformaldehyde and then permeabi-
lized with 0.2% Triton-X 100. Fixed cells were washed with PBS and
nuclei were stained with DAPI solution and the cells were incubated
with anti-hTERT antibody, and the antibody was detected usinganti-mouse IgG conjugated with Taxes Red (Molecular Probes, Eu-
gene, OR). Nuclear morphology and hTERT was evaluated by ﬂuores-
cence microscopy.2.12. Statistical analysis
Scion Imaging software (http://www.scioncorp.com) was used for
quantiﬁcation of Western blots, RT-PCR products, EMSA data, and
ChIP assay data. Statistical analyses were conducted using SigmaPlot
software, and values were presented as mean ± S.D. Signiﬁcant diﬀer-
ences between the groups were determined using the unpaired Stu-
dents t-test. A value of *P < 0.05 was accepted as an indication of
statistical signiﬁcance3. Results
3.1. Gossypol suppresses cell proliferation and viability in
leukemia cells
We ﬁrst investigated the eﬀect of gossypol on cell viability
and growth in diﬀerent myeloid leukemia cells, including
U937, K562, HL-60, and THP-1. As shown in Fig. 1A and
B, treatment with gossypol signiﬁcantly decreased cell viability
and proliferation in a concentration-dependent manner in all
leukemia cells. Treatment with 20 lM gossypol for 24 h signif-
icantly reduced the viability and growth of all the leukemia
cells tested by at least 30%. Moreover, treatment with gossypol
concentrations above 10 lM was associated with cell shrink-
age, a phenomenon not seen in the control cells (Fig. 1C). In
order to determine whether gossypol-induced anti-prolifera-
tion and cell death were associated with apoptosis, we next
evaluated the sub-diploid DNA (sub-G1) and annexin-V
content using ﬂow cytometry. As shown in Figs. 1D and 1E,
gossypol treatment resulted in an increase of the sub-G1 phase
population and annexin-V intensity in all leukemia cells. We
also investigated PARP involvement during gossypol-induced
apoptosis in leukemia cells. As shown in Fig. 1F, gossypol
exposure signiﬁcantly increased cleavage of PARP. These data
indicate that gossypol inhibits cell proliferation and leads to
apoptotic death in leukemia cells.3.2. Gossypol represses telomerase activity and transcriptional
level of hTERT
Cells were cultured in the presence of gossypol for 24 h and
telomerase activity was measured by TRAP-ELISA kit. As
shown in Fig. 2A, gossypol treatment resulted in a signiﬁcant
and dose-dependent reduction of telomerase activity in four
leukemia cells. Treatment with 5 lM gossypol did not signiﬁ-
cantly aﬀect telomerase activity in HL60 and K562. Moreover,
treatment with 20 lM gossypol suppressed telomerase activity
by approximately 30% in all cells tested. The gossypol-induced
decrease in telomerase activity was not cell-type speciﬁc be-
cause a similar eﬀect was observed in hepatoma cell line Hep3B
and prostate cancer cell line PC3 (Fig. 2B). However, we can-
not ﬁnd any changes in normal mouse splenocytes in the pres-
ence of gossypol.
Expression of the hTERT is known to regulate telomerase
activity in a variety of cancer cells, therefore, we attempted
to elucidate whether the observed inhibitory eﬀect of gossypol
on telomerase activity was due to the repression of hTERT
expression in leukemia cells. We used RT-PCR and Western
blotting analysis to examine changes in hTERT expression fol-
lowing treatment with gossypol in U937 cells. As indicated in
Fig. 1. Gossypol induces apoptosis in human leukemia cells. Cells were seeded at 1 · 105 cells/ml and treated with the indicated concentrations of
gossypol for 24 h. Cell (A) viability and (B) number were determined by MTT assay and hemocytometer counts of trypan blue-excluding cells,
respectively. (C) The morphology of cells incubated with or without gossypol for 24 h was examined under light microscopy (400·). (D) Cells were
harvested and 10000 events were analyzed for each sample. DNA content is represented on the x-axis and the number of cells counted is represented
on the y-axis. Data are representative of three independent experiments. (E) Apoptotic annexin-V population was observed in gossypol-treated cells.
(F) The cells treated with the indicated concentrations of gossypol for 24 h, were lysed for protein extraction. Samples were subjected to 10% SDS–
PAGE and Western blotting for detection of speciﬁc proteins as indicated. b-Actin was used as a loading control. Data are expressed as overall
mean ± S.D. from three independent experiments. Statistical signiﬁcance was determined by Students t-test (*P < 0.05 vs. vehicle control).
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hTERT decreased in a dose-dependent manner following treat-
ment with gossypol. In addition, gossypol signiﬁcantly induced
sub-G1 phase of other cancer cells, such as Hep3B and PC3,however, normal mouse splenocytes had no eﬀect on cytotox-
icity (Fig. 2E). These results suggest that the downregulation
of telomerase activity following gossypol treatment is due to
downregulation of hTERT expression.
Fig. 2. Gossypol inhibits telomerase activity and hTERT expression. (A) After 24 h incubation with gossypol, telomerase activity of leukemic cancer
cells was measured using a TRAP-ELISA and TRAP assay (B). (C) Total RNA was isolated using Trizol reagent. One micrograms of RNA were
reverse-transcribed. The resulting cDNA was subjected to PCR with hTERT primers, and visualized by EtBr staining. GAPDH was used as an
internal control. (D) Equal amounts of cell lysate were subjected to Western blot analysis with speciﬁc antibodies (anti-hTERT). b-Actin was used as
an internal loading control. (E) DNA content was analyzed by ﬂow cytometry. Arrows indicate the population of cells in the sub-G1 phase. The
results are from one representative experiment of three performed that showed similar patterns. Data are expressed as mean ± S.D. of three
independent experiments. The signiﬁcance was determined by Students t-test (*P < 0.05 vs. untreated control).
Fig. 3. Gossypol downregulates c-Myc DNA binding activity at promoter regions of hTERT. Cells were incubated with the indicated concentrations
of gossypol for 24 h. (A) Total protein was subjected to 10% SDS–PAGE, transferred to nitrocellulose membrane and protein levels were analyzed by
Western blotting using anti-c-Myc antibody and then normalized to b-actin. (B) c-Myc DNA binding activity was analyzed by LightShift
chemiluminescent EMSA kit as described in Section 2. (C) ChIP assay was performed using antibodies against c-Myc. Total sonicated chromatin was
used to use as input. Negative controls were performed using antibody against rabbit IgG, respectively. I, input.
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The hTERT gene has an important upstream promoter re-
gion with two c-Myc binding sites. Furthermore, c-Myc has
previously been shown to directly regulate telomerase activity[11]. Because c-Myc is involved in hTERT regulation, we at-
tempted to determine whether gossypol alters c-Myc expres-
sion in U937 cells. Western blotting assay reveals that
treatment with concentrations of gossypol greater than
10 lM reduced c-Myc protein levels in U937 cells (Fig. 3A).
Fig. 4. Gossypol inhibits phosphorylation of Akt and thereby prevents translocation to the nucleus in U937 cell. (A) Cells were incubated with the
indicated concentrations of gossypol for 24 h. Total protein was subjected to 10% SDS–PAGE, transferred to nitrocellulose membranes, and protein
levels were analyzed by Western blotting using anti-p-Akt Ser473 or anti-Akt antibodies, and then normalized to b-actin. (B) The lysates were
subjected to immunoprecipitation with the anti-hTERT antibody and then blotted with anti-p-Akt substrate or anti-hTERT antibody. (C) Gossypol-
treated cells were stained with anti-hTERT and DAPI solution, then counterstained with anti-mouse IgG conjugated Taxes Red antibody. Cells were
analyzed by ﬂuorescence microscopy (400·). The results are from one representative experiment of three performed that showed similar patterns.
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Myc DNA binding activity in U937 cells. To further investi-
gate the exact mechanism of gossypol on the regulation of
hTERT expression, ChIP assay was performed to examine
the binding of c-Myc on the hTERT promoter regions. As
shown in Fig. 3C, our results showed that gossypol attenuated
c-Myc binding to the promoter regions of hTERT. These re-
sults indicate that gossypol attenuates hTERT gene expression
through suppression of c-Myc binding on the regulatory re-
gions of hTERT.
3.4. Gossypol inactivates Akt and prevents phosphorylation of
hTERT, thereby inhibiting nuclear translocation in
U937cells
Akt is well known to enhance human telomerase activity
through phosphorylation of hTERT [9]. Therefore, we ana-
lyzed whether the decrease of telomerase activity by gossypol
treatment was associated with inactivation of Akt. As shown
in Fig. 4A, total Akt levels did not change following treatment
with various doses of gossypol. In contrast, levels of p-Akt
were decreased in a dose-dependent manner. Because activated
Akt phosphorylates hTERT, we next tested that gossypol de-
creases hTERT phosphorylation at a putative Akt phosphory-
lation site. As shown in Fig. 4B, treatment with gossypol
signiﬁcantly decreased the phosphorylation of hTERT. Phos-
phorylation of hTERT is also necessary for its nuclear translo-
cation, we subsequently examined the localization of hTERT
with or without gossypol treatment. As shown in Fig. 4C,
hTERT protein is localized to the nucleus in gossypol-treated
cells and to the cytoplasm in control cells. However, treatment
with 10 lM of gossypol decreased overall hTERT staining
intensity and was accompanied by a complete loss of nucleus
in U937 cells. Theses results suggest that gossypol decreased
phosphorylation of hTERT and thereby inhibited its translo-
cation to the nucleus.4. Discussion
Normal cells lose up to 300 bp of DNA per cell division in
telomeres that ﬁnally leads to senescence, however, approxi-
mately 90% cancer cells escape this phenomenon through the
activation of telomerase. Therefore, it has thought that the
suppression of telomerase activity is good treatment against
a lot of cancer cells. Recently, anti-oxidant and polyphenolic
compounds extremely suppressed telomerase activity and re-
sulted in anti-proliferation and apoptosis in vitro in cancer
cells [21–24]. A previous study also demonstrated that gossy-
pol could inhibit human immunodeﬁciency virus (HIV) activ-
ity by targeting the non-nucleotide inhibitor of reverse
transcriptase [25]. This result indirectly provided evidence that
gossypol also inhibits telomerase activity. However, the role of
gossypol in altering telomerase activity has yet to be eluci-
dated. Therefore, we ﬁrst attempted to prove that gossypol
modulates telomerase activity and hTERT expression in leuke-
mia cells. Gossypol treatment caused a dose-dependent de-
crease in transcription of hTERT and in telomerase activity.
hTERT is tightly regulated by various transcription factors
and the hTERT core promoter is known to have two c-Myc,
ﬁve Sp1, one Ets, and two Inr binding sites [26,27]. In partic-
ular, the role of c-Myc in the regulation of hTERT transcrip-
tion has been researched extensively [28]. c-Myc has been
shown to bind to the c-Myc recognition sequence (E-box) at
the promoter of hTERT and activate hTERT transcription
[11]. In this study, we found that c-Myc protein levels de-
creased and c-Myc DNA binding activity was also repressed
by gossypol treatment in U937 cells following treatment with
gossypol. These results support the contention that c-Myc con-
trols the transcription of hTERT and suggest that the repres-
sion of telomerase activity could be via the decreased c-Myc
DNA binding activity. Because c-Myc is also methylation-sen-
sitive in its binding [29,30], we cannot role out a possibility that
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ies also established that other transcription factors, such as SP-
1, AP-1, and NF-jB, may also aﬀect hTERT expression and
thus telomerase activity [30–32]. Therefore, additional experi-
ments are necessary in order to investigate the role of AP-1,
SP-1 or NF-jB in gossypol-induced suppression of telomerase
activity.
Of all the telomerase subunits, hTERT has received the most
attention due to the revelation that telomerase activity may be
tightly regulated by direct phosphorylation of the hTERT by
Akt [13]. Phosphorylation of hTERT may be a particularly
important mechanism to control hTERT nuclear transloca-
tion. Translocation of hTERT from a presumably non-func-
tional cytosolic location to a physiologically relevant nuclear
localization may be one important mechanism to regulate tel-
omerase function in cells. In the present study, we observed
that gossypol treatment downregulated p-Akt without aﬀect-
ing the total levels of Akt. Moreover, phosphorylation and
translocation of hTERT were also decreased signiﬁcantly after
gossypol treatment. These results clearly suggest that gossypol
posttranslationally regulates hTERT through phosphorylation
by Akt. Further experiments are necessary in order to deter-
mine whether gossypol also regulates activation of mitogen-
activated protein kinases, which are well known to activate tel-
omerase via regulation of hTERT [33–35].
In summary, our results demonstrated that gossypol induces
apoptosis in human leukemia cells. This induction of apoptosis
was associated with the downregulation of telomerase activity
through transcriptional and posttranslational modiﬁcation of
hTERT. In addition, gossypol also deactivated transcriptional
factors such as c-Myc, and Sp1, and Akt. In view of accumu-
lating evidence that gossypol may be a therapeutic agent to
suppress telomerase activity, further eﬀorts are necessary in or-
der explores this therapeutic strategy.
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